Bliss GVS Pharma Ltd

Bliss GVS Pharma | 506197

Live

₹524.30

+₹0.16 (+0.03%)

As on 10/07/26, 8:24 PM

Market Cap5,558.94 CR

Current Price₹524.3

High / Low₹553 / 118

PE Ratio17.65

Book Value₹112.76

Dividend Yield0.23%

ROCE17.02%

ROE8.75%

Face Value₹2.00

Current Vol.4,56,537

Average Vol.---

ISININE416D01022

PB Ratio1.91

Debt to Equity0.05

Net Profit Margin14.53

Operating Margin25.36

Share Price Chart - Bliss GVS Pharma Ltd

+₹0.00 (+0.00%)6M

Stock Performance

₹524.15₹525

₹524.3

Previous CloseToday's Open

₹118₹553

₹524.3

52W Low52W High

₹525Today's Open

₹524.15Previous Close

4,56,537Volume

₹11852W Low

₹55352W High

Ratios

No data available

About Company

Bliss GVS Pharma Limited was originally incorporated as a Private limited company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006
The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products
The Company has its manufacturing facility at Palghar which is WHO GMP approved
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards
The company commenced its business in 1985
In 1994 the company introduced a new pharmaceutical product VAGID
During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR)
During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd
During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action

Ethics: Bliss GVS Pharma Ltd is flagged for

Adequate

---

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI66.55

SMA 20488.54

SMA 50394.87

SMA 100311.70

SMA 200236.29

SMA 10515.73

MACD_12_26_Days34.24

EMA10Day507.51

EMA20Day484.69

EMA50Day414.52

MACD_12_26_9_Days-3.91

EMA100Day342.21

EMA200Day273.21

Pivot Points

Volume Analysis

Delivery

Total Volume

Growth Rate

Revenue Growth14.50%

ROE12.01%

EBITDA Margin25.36%

All figures in ₹ Crores

Indicators	2026	2025	2024	2023	2022
Revenue	927.11	809.73	770.24	751.59	747.45
Interest	12.01	8.12	6.91	10.36	4.74
Expenses	763.08	683.04	619.62	634.26	629.11
Financing Profit	237.57	163.18	179.36	135.11	149.83
Financing Margin %	26%	20%	23%	18%	20%
Other Income	73.53	36.49	28.74	17.79	31.49
Depreciation	33.48	29.42	26.38	18.67	17.33
Profit before tax	189.59	125.64	116.87	106.07	54.17
Tax %	29%	28%	30%	28%	57%
Net Profit	134.73	90.26	81.58	76.73	23.13
EPS in Rs	12.23	8.02	7.23	6.83	1.46

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
MATEUS LTD	29 Jun ‘26	Purchase	11,50,000	₹490	40.79%
ARIAN INVESTMENT LTD	29 Jun ‘26	Sell	11,50,000	₹490	40.79%
MATEUS LTD	05 Feb ‘26	Purchase	14,00,000	₹180.1	70.48%
ARIAN INVESTMENT LTD	05 Feb ‘26	Sell	14,00,000	₹180.1	70.48%
MATEUS LTD	20 Oct ‘25	Purchase	26,00,000	₹150.6	1008.16%
ARIAN INVESTMENT LTD	20 Oct ‘25	Sell	26,00,000	₹150.6	1008.16%

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

08 Jul 2026

Final Dividend (₹1)

Recommended Final dividend of 100%, i.e. 1 Rupee per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2026, subject to approval of the shareholders in the forthcoming 41st Annual General Meeting of the Company

12 May 2026

18 Feb 2026

Interim Dividend (₹0.5)

Declared the Interim dividend of 50% i.e. 0.50 paisa per equity share on face value of Re.1/- each for the financial year 2025-2026. The Interim Dividend shall be paid within 30 days from the date of its declaration.

10 Feb 2026

31 Jul 2025

AGM

12 May 2025

24 Jul 2025

Final Dividend (₹0.5)

Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs.1/- each for the financial year ended March 31, 2025, subject to approval of the shareholders in the forthcoming 40th Annual General Meeting of the Company (40th AGM');

12 May 2025

25 Jul 2024

AGM

02 May 2024

19 Jul 2024

Final Dividend (₹0.5)

Outcome of Board Meeting held on Thursday, May 02, 2024 Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company (39th AGM').

02 May 2024

19 Jul 2023

AGM

12 May 2023

13 Jul 2023

Final Dividend (₹0.5)

Recommended Final Dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2023, subject to approval of the shareholders in the forthcoming 38th Annual General Meeting of the Company ('38th AGM')

11 May 2023

28 Jun 2022

AGM

02 May 2022

21 Jun 2022

Final Dividend (₹0.5)

Outcome Of Board Meeting Held On Saturday, April 30, 2022 Recommended Final dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/-each for the financial year ended March 31, 2022. Pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and in continuation to our intimated details on April 30, 2022 relating to Book Closure, please note that Bliss GVS Pharma Limited ('the Company') has fixed Tuesday, June 21, 2022 as the Record Date for determining entitlement of members to Final Dividend for the financial year ended on March 31, 2022. Payment of Dividend, subject to approval of the members at the ensuing AGM, will be made on or after Wednesday, June 29, 2022. (As Per BSE Announcement Dated on 06.06.2022)

02 May 2022

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
521	5,527	42	5	33	0	14.53%
1,935	4,64,331	37	6	30	0	19.78%
6,836	1,81,466	69	11	59	0	23.41%
4,903	1,65,952	76	20	50	1	11.09%
1,439	1,16,229	31	3	23	0	9.92%
1,151	1,14,763	21	4	17	0	19.86%
2,496	1,14,128	20	5	16	0	14.56%
2,525	1,04,275	52	6	36	0	14.39%
1,246	1,03,959	26	3	17	0	12.34%
1,565	90,875	26	2	17	0	10.98%

Showing 10 of 134 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

DIXONDixon Technologies (India) Ltd
₹13,421-56 (-0.42%)

Frequently Asked Questions

What is Share Price of Bliss GVS Pharma Ltd?

The current share price of Bliss GVS Pharma Ltd (Bliss GVS Pharma) is ₹524.30. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Bliss GVS Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Bliss GVS Pharma Ltd is 524.30. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd has a 52-week high of ₹553.00 and a 52-week low of ₹118.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd offers a dividend yield of 0.10%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Bliss GVS Pharma Ltd?

The Earnings Per Share (EPS) of Bliss GVS Pharma Ltd is ₹12.44. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd has a Return on Equity (ROE) of 8.75%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds. Play Video